Brief: Achilles Therapeutics Gives Positive Phase I/IIa Update On CNet At ESMO IO
06/12/2022 12:02
Dec 6 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS PRESENTS ENCOURAGING PHASE I/IIA
UPDATE ON
CLONAL NEOANTIGEN REACTIVE T CELLS IN ADVANCED NSCLC AND
MELANOMA AT ESMO IO CONGRESS 2022
* ACHILLES THERAPEUTICS PLC- ADDITIONAL MONOTHERAPY DATA AND
INITIAL ANTI-PD-1 COMBINATION DATA EXPECTED IN 2023
Source text for Eikon: ID:nGNX8zPQTj
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement